MedTrace Logo

Efficacy and Safety of BP1.4979 in Smoking Cessation

NCT01785147 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2015-01-21

No results posted yet for this study

Summary

Clinical study which aim is to assess in heavy smokers willing to quit smoking the efficacy and the safety profile of BP1.4979 for smoking cessation on the total abstinence measured by subject diary and confirmed by exhaled CO (abstinent \< 10 ppm).

Conditions

  • Tobacco Addiction

Interventions

DRUG

BP1.4979

BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Henri-Jean AUBIN, MD, Ph.D · Hôpital Paul Brousse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-07-31
Completion
2014-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01785147 on ClinicalTrials.gov